Abstract:Levodopa is the most effective drug for treating the symptoms of Parkinsons' disease(PD). But its long-term use is associated with loss of efficacy and the onset of motor complications. With the producing of the concept that continuous dopaminergic stimulation would avoid the onset of complications, such as involuntary movements, treatment approaches that might provide more constancy, and therefore physiological and dopamine receptor stimulation have been sought. Transdermal drug delivery is a treatment approach that is not only capable of providing a constant rate of drug delivery, but is also non-invasive and relatively simple to use. Previous trials of transdermal drug delivery in PD, with piribedil and naxagolide for example, have been unsuccessful. In contrast, some randomized, double-blind, placebo-controlled trials conducted with rotigotine showed the positive and encouraging results. Transdermal delivery of dopaminergic agents has completed Phase Ⅲ development, and regulatory approval is expected in the near future.

Transdermal Delivery of Dopaminergic Agents